Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Lenvatinib and Pembrolizumab in RCC with IVC Tumor Thrombus
NCT05319015Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and pembrolizumab in renal cell carcinoma (RCC), sponsored by UT Southwestern Medical Center. Primary endpoints: Disease Control Rate at 12 weeks, Local and Metastatic Progression Rate at 12 weeks and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05319015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319015.